1Taube J,Halsall D,Baqlin T.Influence of cytochrome P2450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over anticoagulation in patients on long2term treatment.Blood,2000,96(5):1816-1819
2Aithal G P,Day C P,Kesteven P J,et al.Association of polymorphisms in the cytochrome P450 CYP2C9 with wadarin dose requirement and risk of bleeding complications Lancet,1999,353(9154):717-719
3Margaglione M,Colaizzo D,D'Andrea G,et al.Genetic modulation of oral anticoagulation with warfarin.Throm b Haem ost,2000,84(5):775-778
4Yuan H Y,Chen J J,LceM T,et al.A novel functional VKORC1 promoter polymorphism is associated with inter-individual and interethnic differences in warfarin sensitivity.Hum M ol Genet,2005,14(13):1745-1751
5Sconce E A,Daly A K,Khan T I,et al.APOE genotype makes a small contribution to warfarin dose requirements.Pharmacogenat Genomics,2006,16(8):609-611
6Martin LA,Mehta SD.Diminished anticoagulant effects of warfarin with concomitant mercaptopurine therapy.Pharmaco therapy,2003,23(2):260-264
7Jones CB,Fugate SE.Levofloxacin and warfarin interaction.Ann Pharmaco ther,2002,36(10):1554-1557
8Goldstoin JA.Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.Br J Clin Pharmacol,2001,52(4):349-355
9Chan TY.Interaction between warfarin and danshen(Salvia mitiorriza).Ann Pharmacother,2001,35(4):501-504
10Izzo AA,DI Carlo G,Borelli F,et al.Cardiovascular Phamacotherpy and herbal medicine:the risk of drug interaction.Int J Cardiol,2005,98(1):1-14
